Crinetics Q2 net loss $74.1M; CFO Wilson departs; paltusotine NDA on track for H2 2024

Crinetics Pharmaceuticals, Inc.

2024-Q2 EPS reported -$1.86 revenue$1,039,000

Net loss of $74.1M in Q2 2024 vs $51.0M in Q2 2023; R&D expenses rose to $58.3M from $40.6M.
CFO Marc Wilson stepping down for personal reasons; search for successor initiated; he will remain until replacement on-boarded.
Paltusotine NDA for acromegaly on track for H2 2024; Phase 3 program for carcinoid syndrome expected to begin by end of 2024.
Topline data from atumelnant Phase 2 studies in CAH and Cushing's syndrome anticipated by end of 2024.
Unrestricted cash $863M as of June 30, 2024; management expects funding into 2028.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Marc Wilson

Chief Financial Officer

CRNX · Crinetics Pharmaceuticals, Inc.

Filed: August 8, 2024, 7:59 PM ET

On August 5, 2024, Marc Wilson notified the Company of his decision to step down from his position as Chief Financial Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Marc Wilson departed as Chief Financial Officer at Crinetics Pharmaceuticals, Inc..

Action: stepped down
Role: Chief Financial Officer

Exact text from the filing

On August 5, 2024, Marc Wilson notified the Company of his decision to step down from his position as Chief Financial Officer of the Company.

View on SEC.gov

Crinetics Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-093951

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.